Is dihydrofolate reductase a drug target?
In this field, dihydrofolate reductase (DHFR) is an important enzyme in nucleic and amino acid synthesis and an extensively studied drug target over the past 50 years.
Why is dihydrofolate reductase important?
Dihydrofolate reductase is a small enzyme that plays a supporting role, but an essential role, in the building of DNA and other processes. It manages the state of folate, a snaky organic molecule that shuttles carbon atoms to enzymes that need them in their reactions.
What does a dihydrofolate reductase inhibitor do?
A substance that can build up in cancer cells and block them from using folate. Folate is a nutrient that rapidly dividing cells need to make DNA. Blocking folate use helps keep cancer cells from growing and may kill them.
What is the function of dihydrofolate reductase in bacteria?
Dihydrofolate reductase catalyzes the reduction of dihy- drofolate with NADPH as the reducing substrate. This enzyme is of special interest because several of its inhibitors have been used in the treatment of neoplastic disease, malaria, bacterial infections, psoriasis, and other disorders (1).
Where is dihydrofolate reductase found?
It is found in the q11→q22 region of chromosome 5. Bacterial species possess distinct DHFR enzymes (based on their pattern of binding diaminoheterocyclic molecules), but mammalian DHFRs are highly similar.
Is methotrexate a dihydrofolate reductase inhibitor?
Methotrexate. Methotrexate is a dihydrofolate reductase inhibitor that is used in the treatment of autoimmune inflammatory diseases such as RA. Methotrexate inhibits inflammation even in low-dose treatment. Inflammatory markers as IL-6, CRP, and TNF-α are reduced in patients treated with methotrexate.
What is human dihydrofolate reductase?
Dihydrofolate reductase converts dihydrofolate into tetrahydrofolate, a methyl group shuttle required for the de novo synthesis of purines, thymidylic acid, and certain amino acids.
Which drug is dihydrofolate reductase inhibitor?
Methotrexate. Methotrexate is a dihydrofolate reductase inhibitor that is used in the treatment of autoimmune inflammatory diseases such as RA. Methotrexate inhibits inflammation even in low-dose treatment.
Do humans have dihydrofolate reductase?
In humans, the DHFR enzyme is encoded by the DHFR gene. It is found in the q11→q22 region of chromosome 5. Bacterial species possess distinct DHFR enzymes (based on their pattern of binding diaminoheterocyclic molecules), but mammalian DHFRs are highly similar….Dihydrofolate reductase.
| Available protein structures: | |
|---|---|
| PDBsum | structure summary |
What drugs inhibit dihydrofolate reductase?
DHFR inhibitors used for antiparasitic therapy include pyrimethamine, trimethoprim, proguanil, and trimetrexate.
Which of the following drug is dihydrofolate reductase inhibitor?
Methotrexate. Methotrexate is a dihydrofolate reductase inhibitor used in the treatment of leukemia, lymphomas (including central nervous system lymphoma), choriocarcinoma, breast cancer, osteosarcoma, and leptomeningeal metastases.
Which of the following compounds inhibits dihydrofolate reductase activity?
Which antimalarial drug inhibit the dihydrofolate reductase?
falciparum dihydrofolate reductase (DHFR), which is inhibited by the antimalarials PYR and cycloguanil (CG) (Fig.
Which drug inhibits dihydrofolate reductase and the subsequent production of purines?
Methotrexate
Methotrexate inhibits DHFR with a high affinity, thus reducing the amount of tetrahydrofolates required for the synthesis of pyrimidine and purines.
How does methotrexate inhibit dihydrofolate reductase?
Methotrexate inhibits DHFR with a high affinity, thus reducing the amount of tetrahydrofolates required for the synthesis of pyrimidine and purines. Consequently, RNA and DNA synthesis is stopped and the cancer cells die.
How does trimethoprim inhibit dihydrofolate reductase?
Trimethoprim owes its activity to powerful inhibition of bacterial dihydrofolate reductase, which is the enzyme step after the step in folic acid synthesis blocked by sulfonamides. Trimethoprim is 50,000 to 100,000 times more active against bacterial dihydrofolate reductase than against the human enzyme.
What is the bacterial target of trimethoprim?
Trimethoprim exerts antimicrobial activity by blocking the reduction of dihydrofolate to tetrahydrofolate, the active form of folic acid, by susceptible organisms.
What is the bacterial target and general mechanism of action of trimethoprim?
Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) – in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival.
What does trimethoprim treat?
Trimethoprim is an antibiotic. It’s used to treat and prevent urinary tract infections (UTIs), such as cystitis. Occasionally, trimethoprim is used to treat other types of infections, such as chest infections and acne. Trimethoprim is available on prescription.
What is the target for trimethoprim?
What is dihydrofolate reductase?
Dihydrofolate reductase is an enzyme that converts dihydrofolate to tetrahydrofolate and is involved in purines and thymidylate synthesis. It is encoded by the human DHFR gene. Antifolate drugs, methotrexate (MTX) and trimetrexate, can tightly bind to DHFR and inhibit DNA synthesis and cell proliferation.
What is the role of DHFR in the synthesis of tetrahydrofolate?
Dihydrofolate reductase (DHFR) is a ubiquitous enzyme, which plays an essential role in the biosynthesis of tetrahydrofolate cofactors. It catalyzes the NADPH-dependent reduction of dihydrofolate to tetrahydrofolate (see Fig. 1 under comments).
What is the function of dihydrofolate?
Dihydrofolate reductase is an enzyme that converts dihydrofolate to tetrahydrofolate and is involved in purines and thymidylate synthesis. It is encoded by the human DHFR gene.
How is folic acid used to treat DHFR deficiency?
Folic acid should be avoided in the treatment of DHFR deficiency because DHFR constitutes the only enzyme that catalyzes the conversion of folic acid to dihydrofolate. Infants should be promptly supplemented with 5 to 10 mg/kg body weight of oral folinic acid given daily as a single dose.